Market potential DiaPharma operates in the biotechnology research sector with a focus on thrombosis and haemostasis, platelet function, liver disease, apoptosis, and metabolic disease, suggesting multiple cross-selling opportunities for test kits, reagents, and instruments across related labs and research groups.

Growth signals Revenue is in the $10M-$25M range with a lean employee base, indicating room for targeted sales expansion through bankable product bundles, higher average order value, and expanded service offerings to existing customers.

Event presence Active participation in industry events such as ISLH indicates opportunities to engage key decision makers, showcase new technologies, and accelerate pipeline development through speaking engagements and demonstrations.

Digital readiness A modern tech stack including Shopify, MySQL, and analytics tools positions DiaPharma for streamlined e-commerce and data-driven marketing, enabling targeted campaigns and improved lead capture for lab procurement.

Key personnel Recent hires in 2022 and ongoing science-focused leadership suggest potential for specialized product evangelists and technical sales support to drive adoption of high-complexity assays and instrument platforms.